Strauß, Arne

[["dc.bibliographiccitation.artnumber","574"],["dc.bibliographiccitation.journal","SpringerPlus"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resistance mechanisms occurring under such treatments. In this study we used CRPC cell models VCaP and LNCaP as well as AR-negative PC-3- and non-neoplastic epithelial BPH-1-cells treated with 5, 10 or 25 mu mol/L abiraterone hydrolyzed from abiraterone acetate (AA). The origin of CYP17A1 up-regulation under AA treatment was investigated in CRPC cell models by qRT-PCR and western-blot procedures. AA treatments of AR positive CRPC cell models led to decreased expression of androgen regulated genes such as PSA. In these cells diminished expression of androgen regulated genes was accompanied by an up-regulation of CYP17A1 expression within short-term treatments. No such effects became evident in AR-negative PC-3 cells. AR directed siRNA (siAR) used in VCaP cells significantly reduced mRNA expression and AR protein abundance. Such interference with AR signalling in the absence of abiraterone acetate also caused a marked up-regulation of CYP17A1 expression. Down-regulation of androgen regulated genes occurs in spite of an elevated expression of CYP17A1, the very target enzyme for this drug. CYP17A1 up-regulation already takes place within such short treatments with AA and does not require adaptation events over several cell cycles. CYP17A1 is also up-regulated in the absence of AA when AR signalling is physically eliminated by siAR. These results reveal an immediate counter-regulation of CYP17A1 expression whenever AR-signalling is inhibited adequately but not a persisting adaptation yielding drug resistance."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG)"],["dc.identifier.doi","10.1186/2193-1801-3-574"],["dc.identifier.isi","000359105300002"],["dc.identifier.pmid","25332874"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32049"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","2193-1801"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Lisney, Anna Rebecca; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Leitsmann, Conrad; 2Department of Urology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; conrad.leitsmann@med.uni-goettingen.de (C.L.); astrauss@med.uni-goettingen.de (A.S.)"],["dc.contributor.affiliation","Strauß, Arne; 2Department of Urology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; conrad.leitsmann@med.uni-goettingen.de (C.L.); astrauss@med.uni-goettingen.de (A.S.)"],["dc.contributor.affiliation","Meller, Birgit; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Bucerius, Jan Alexander; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Sahlmann, Carsten-Oliver; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.author","Lisney, Anna Rebecca"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauß, Arne"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bucerius, Jan Alexander"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2022-08-04T08:33:18Z"],["dc.date.available","2022-08-04T08:33:18Z"],["dc.date.issued","2022-07-26"],["dc.date.updated","2022-08-03T12:10:10Z"],["dc.description.abstract","The combination of positron emission tomography (PET)-diagnostics with ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic milestone in the situation of biochemical recurrence of prostate cancer and is gaining importance in primary diagnostics, providing a highly specific and sensitive diagnostic method in various clinical situations. However, the clinical application of this method requires a comprehensive knowledge of its advantages and disadvantages, potential pitfalls and influencing factors. This review aims to provide a practical clinical review of the currently available background data on PSMA PET/CT, as well as the clinical implications. Although a large amount of data already exist, a thorough analysis is complicated by study heterogeneity, showing the need for future systematic and prospective research.\r\n \r\n \r\n Abstract\r\n The importance of PSMA PET/CT in both primary diagnostics and prostate cancer recurrence has grown steadily since its introduction more than a decade ago. Over the past years, a vast amount of data have been published on the diagnostic accuracy and the impact of PSMA PET/CT on patient management. Nevertheless, a large heterogeneity between studies has made reaching a consensus difficult; this review aims to provide a comprehensive clinical review of the available scientific literature, covering the currently known data on physiological and pathological PSMA expression, influencing factors, the differences and pitfalls of various tracers, as well as the clinical implications in initial TNM-staging and in the situation of biochemical recurrence. This review has the objective of providing a practical clinical overview of the advantages and disadvantages of the examination in various clinical situations and the body of knowledge available, as well as open questions still requiring further research."],["dc.identifier.doi","10.3390/cancers14153638"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112630"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.journal","BMC Urology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Loertzer, Hagen"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf Herrmann"],["dc.contributor.author","Schneider, Philine"],["dc.date.accessioned","2018-11-07T09:23:37Z"],["dc.date.available","2018-11-07T09:23:37Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: To date, elective nephron-sparing surgery is an established method for the exstirpation of renal tumors. While open partial nephrectomy remains the reference standard of the management of renal masses, laparoscopic partial nephrectomy (LPN) continues to evolve. Conventional techniques include clamping the renal vessels risking ischaemic damage of the clamped organ. Thus, new techniques are needed that combine a sufficient tissue incision for exstirpation of the tumor with an efficient coagulation to assure haemostasis and abandon renal vessel clamping in LPN. Laser-excision of renal tumors during laparoscopic surgery seems to be a logical solution. Methods: We performed nephron-sparing surgery without clamping of the renal vessels in 11 patients with a renal tumor in exophytic position (mean size 32 mm, ranging 8-45 mm) by laser-supported LPN. Results: Regular ultrasound monitoring and insertion of a temporary drainage showed no evidence of postoperative hemorrhage. All tumors were removed with a histopathologically confirmed surrounding margin of normal renal tissue (R0 resection). Serum creatinine, hemoglobin, and hematocrit were nearly unaltered before and after surgery. Conclusions: The experience won in these patients have confirmed that laser-assisted LPN without clamping of the renal vessels could be a safe and gentle alternative to classic partial nephrectomy in patients with exophytic position of renal tumors."],["dc.identifier.doi","10.1186/1471-2490-13-31"],["dc.identifier.isi","000321514400001"],["dc.identifier.pmid","23786969"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9135"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29624"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2490"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Laser-supported partial laparoscopic nephrectomy for renal cell carcinoma without ischaemia time"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","122"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The Open Public Health Journal"],["dc.bibliographiccitation.lastpage","133"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.date.accessioned","2019-07-09T11:45:23Z"],["dc.date.available","2019-07-09T11:45:23Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose: To summarize the current evidence on preventive services utilization in cancer survivors. Methods: A systematic literature review and meta-analysis was conducted in February 2016. Studies were included if they compared the utilization of influenza vaccination, cholesterol/lipid testing, bone densitometry, or blood pressure measurement among survivors of adulthood cancer to cancer-free controls. Random effects meta-analyses were conducted to pool estimates. Results: Literature search identified 3740 studies of which 10 fulfilled the inclusion criteria. Cancer survivors were significantly more likely to utilize bone densitometry (OR=1.226, 95% CI: 1.114 – 1.350, p<0.001) and influenza vaccination (OR=1.565, 95% CI: 1.176 – 2.082, p=0.002) than cancer-free controls. No statistically significant differences were detected for blood pressure measurement and cholesterol/lipid testing (OR=1.322, 95% CI: 0.812 – 2.151, p=0.261; OR=1.046, 95% CI: 0.96 – 1.139, p=0.304). Conclusions: Cancer survivors were more likely to receive influenza vaccinations and bone densitometry. Future studies should evaluate underlying mechanisms and whether the utilization of preventive services translates into prolonged survival of cancer survivors. Implications for Cancer Survivors: Our meta-analysis demonstrated cancer survivors to be more likely to receive the preventive services such as influenza vaccination and bone densitometry than cancer free controls. Still, these results should be interpreted in the context of suboptimal utilization of preventive services in general, and for cancer survivors in specific. Future research should evaluate the underlying mechanisms and whether utilization of preventive services is associated with overall survival in cancer survivors."],["dc.identifier.doi","10.2174/1874944501811010122"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59219"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1874-9445"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Preventive Services Utilization Among Cancer Survivors Compared to Cancer-free Controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","64"],["dc.bibliographiccitation.journal","Urology Case Reports"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leitsmann, Conrad"],["dc.date.accessioned","2019-07-09T11:45:15Z"],["dc.date.available","2019-07-09T11:45:15Z"],["dc.date.issued","2018"],["dc.description.abstract","Primary Bladder Adenocarcinoma is a rare malignancy that has been observed in a heterogeneous pa- tient population. This case report presents a 51 year old female with muscle-invasive primary bladder adenocarcinoma diagnosed in 2008. After transurethral resection and cystectomy with ileum neobladder adjuvant radi- ochemotherapy was administered. Two years later, a symptomatic fistula between neobladder and ileoileal anastomosis was excised, resulting in urinary incontinency. In 2016, the patient shows no signs of disease relapse but suffers from reduction of bladder capacity. This case report presents classical symptoms of adenocarcinoma of the bladder and a possible treat- ment regimen with associated side effects."],["dc.identifier.doi","10.1016/j.eucr.2018.02.006"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15073"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59191"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2214-4420"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Primary bladder adenocarcinoma: Case report with long-term follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","19"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Clinical Pathology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Radzun, Heinz-Joachim"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.date.accessioned","2019-07-09T11:54:07Z"],["dc.date.available","2019-07-09T11:54:07Z"],["dc.date.issued","2012"],["dc.description.abstract","Background Testicular germ cell tumours (TGCTs) are the most common malignancy in young men aged 18–35 years. They are clinically and histologically subdivided into seminomas and non-seminomas. Cadherins are calcium-dependent transmembrane proteins of the group of adhesion proteins. They play a role in the stabilization of cell-cell contacts, the embryonic morphogenesis, in the maintenance of cell polarity and signal transduction. N-cadherin (CDH2), the neuronal cadherin, stimulates cell-cell contacts during migration and invasion of cells and is able to suppress tumour cell growth. Methods Tumour tissues were acquired from 113 male patients and investigated by immunohistochemistry, as were the three TGCT cell lines NCCIT, NTERA-2 and Tcam2. A monoclonal antibody against N-cadherin was used. Results Tumour-free testis and intratubular germ cell neoplasias (unclassified) (IGCNU) strongly expressed N-cadherin within the cytoplasm. In all seminomas investigated, N-cadherin expression displayed a membrane-bound location. In addition, the teratomas and yolk sac tumours investigated also differentially expressed N-cadherin. In contrast, no N-cadherin could be detected in any of the embryonal carcinomas and chorionic carcinomas examined. This expression pattern was also seen in the investigated mixed tumours consisting of seminomas, teratomas, and embryonal carcinoma. Conclusions N-cadherin expression can be used to differentiate embryonal carcinomas and chorionic carcinomas from other histological subtypes of TGCT."],["dc.identifier.doi","10.1186/1472-6890-12-19"],["dc.identifier.fs","593171"],["dc.identifier.pmid","23066729"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8499"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60578"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","N-cadherin expression in malignant germ cell tumours of the testis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Surgery"],["dc.bibliographiccitation.volume","9"],["dc.contributor.affiliation","Reichert, Mathias; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Ploeger, Hannah Maria; 2Department of Pediatrics, University Hospital Bonn, Bonn, Germany"],["dc.contributor.affiliation","Uhlig, Annemarie; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Strauss, Arne; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Henniges, Philipp; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Trojan, Lutz; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Mohr, Mirjam Naomi; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.author","Reichert, Mathias"],["dc.contributor.author","Ploeger, Hannah Maria"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Henniges, Philipp"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Mohr, Mirjam Naomi"],["dc.date.accessioned","2022-12-07T08:25:13Z"],["dc.date.available","2022-12-07T08:25:13Z"],["dc.date.issued","2022-11-23"],["dc.date.updated","2022-12-07T06:37:25Z"],["dc.description.abstract","Purpose\r\nTo evaluate long-term continence rates (12 months) in patients after robot-assisted laparoscopic prostatectomy (RALP) in relation to their cognitive ability (CoAb), which proved to be a predictor for early post-prostatectomy incontinence.\r\n\r\nMaterial & Methods\r\nThis is the 12-month follow-up evaluation of our previously published observational single-center, prospective evaluation of 84 patients who underwent RALP as treatment of their localized prostate cancer between 07/2020 and 03/2021. Post-prostatectomy incontinence (PPI) was measured by asking patients about their 24 h pad usage, whereby 0 pads were considered continent and ≥1 pad was considered incontinent. CoAb was evaluated by performing the Mini-Mental State Examination prior to surgery. Possible predictors for PPI were evaluated using univariate and multivariable logistic regression models.\r\n\r\nResults\r\nMultivariable logistic regression analyses identified early incontinence status and nerve sparing (NS) as independent predictors for PPI after 12 months, resulting in a 5.69 times higher risk for PPI when the loss of urine was between 10 and 50 ml during the early performed pad test (one day after catheter removal) compared to 0–1 ml loss of urine [95% confidence interval (CI): 1.33–28.30, p = 0.024] and a 6.77 times higher risk for PPI, respectively, when only unilateral NS was performed compared to bilateral NS (95% CI: 1.79–30.89, p = 0.007). CoAb lost its predictive value for long-term PPI (p = 0.44).\r\n\r\nConclusion\r\nThe results of this study suggest that PPI is a dynamic, rather than a static condition with a dynamically changing pathophysiology within the first 12 months after RALP. Coping methods and therapies should adapt to this circumstance."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fsurg.2022.1055880"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118457"],["dc.language.iso","en"],["dc.relation.eissn","2296-875X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Understanding long-term continence rates after robot-assisted laparoscopic prostatectomy – one-year follow-up on “Cognitive ability as a non-modifiable risk factor for post-prostatectomy urinary incontinence”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1257"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","1269"],["dc.bibliographiccitation.volume","69"],["dc.contributor.author","Payne, Shannon R."],["dc.contributor.author","Serth, Juergen"],["dc.contributor.author","Schostak, Martin"],["dc.contributor.author","Kamradt, Jorn"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Model, Fabian"],["dc.contributor.author","Day, J. Kevin"],["dc.contributor.author","Liebenberg, Volker"],["dc.contributor.author","Morotti, Andrew"],["dc.contributor.author","Yamamura, S. U."],["dc.contributor.author","Lograsso, Joe"],["dc.contributor.author","Sledziewski, Andrew"],["dc.contributor.author","Semjonow, Axel"],["dc.date.accessioned","2018-11-07T11:25:26Z"],["dc.date.available","2018-11-07T11:25:26Z"],["dc.date.issued","2009"],["dc.description.abstract","BACKGROUND. A prostate cancer (PCa) biomarker with improved specificity relative to PSA is a public health priority. Hypermethylated DNA can be detected in body fluids from PCa patients and may be a useful biomarker, although clinical performance varies between studies. We investigated the performance of candidate PCa DNA methylation biomarkers identified through a genome-wide search. METHODS. Real-time PCR was used to measure four DNA methylation biomarkers: GSTP1 and three previously unreported candidates associated with the genes RASSF2, HIST1H4K, and TFAP2E in sodium bisulfite-modified DNA. Matched plasma and urine collected prospectively from 142 patients referred for prostate biopsy and 50 young asymptomatic males were analyzed. RESULTS. Analysis of all biomarkers in urine DNA significantly discriminated PCa from biopsy negative patients. The biomarkers discriminated PCa from biopsy negative patients with AUCs ranging from 0.64 for HIST1H4K (95% CI 0.55-0.72, P < 0.00001) to 0.69 for GSTPI (95% CI 0.60-0.77, P < 0.00001). All biomarkers showed minimal correlation with PSA. Multivariate analysis did not yield a panel that significantly improved performance over that of single biomarkers. All biomarkers showed greater sensitivity for PCa in urine than in plasma DNA. CONCLUSIONS. Analysis of the biomarkers in urine DNA significantly discriminated PCa from biopsy negative patients. The biomarkers provided information independent of PSA and may warrant inclusion in nomograms for predicting prostate biopsy outcome. The biomarkers' PCa sensitivity was greater for urine than plasma DNA. The biomarker performances in urine DNA should next be validated in formal training and test studies. Prostate 69:1257-1269, 2009. (C) 2009 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/pros.20967"],["dc.identifier.isi","000269176600001"],["dc.identifier.pmid","19459176"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6152"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56620"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","DNA Methylation Biomarkers of Prostate Cancer: Confirmation of Candidates and Evidence Urine is the Most Sensitive Body Fluid for Non-Invasive Detection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Surgery"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-04-14T08:27:57Z"],["dc.date.available","2021-04-14T08:27:57Z"],["dc.date.issued","2021"],["dc.description.abstract","Purpose: Several studies have demonstrated an advantage of 68Ga-PSMA-PET/CT as staging modality for detection of prostate cancer (PCa) metastases. Data concerning metastatic manifestation and impact on PCa development of mesorectal lymph nodes (MLN) is limited. Our investigation describes MLN metastases as index lesion in 68Ga-PSMA PET/CT imaging for recurrent PCa. Methods: Twelve PCa patients with biochemical recurrence (BCR) after primary therapy who prospectively underwent a baseline 68Ga-PSMA-PET/CT initially showed MLN metastases. Eight of these patients received a follow-up 68Ga-PSMA-PET/CT to evaluate treatment response and further evolution. Prostate-specific antigen (PSA)-levels, changes in PSMA-uptake of MLN metastases and further 68Ga-PSMA PET/CT findings were recorded. Results: Median PSA at the first 68Ga-PSMA-PET/CT was 5.39 ng/ml. In all patients therapeutic management changed after the first 68Ga-PSMA-PET/CT. Androgen deprivation therapy (ADT) was initiated in seven of eight patients, one patient restarted initial ADT. Three patients additionally received salvage radiation therapy (sRT) including the prostatic lodge and docetaxel chemotherapy was started in one case. At follow-up, a decrease of PSA-level was detected in all patients (median 2.05 ng/ml) after median 10 months. In six of eight patients we observed a decrease or complete regress of PSMA-uptake in MLN in the follow-up 68Ga-PSMA-PET/CT. Conclusion: MLN metastases detected by 68Ga-PSMA-PET/CT seem to be a relevant localization of tumor manifestation and may serve as index lesion in the treatment of recurrent PCa. Besides the known oncological benefits of ADT and sRT, in case of sole MLN metastases individualized therapy like salvage lymphadenectomy or RT with a defined radiation field could be options for these patients."],["dc.identifier.doi","10.3389/fsurg.2021.637134"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","2296-875X"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e78137"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Becker, Frank"],["dc.contributor.author","Junker, Kerstin"],["dc.contributor.author","Parr, Martin"],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Fuessel, Susanne"],["dc.contributor.author","Toma, Marieta"],["dc.contributor.author","Grobholz, Rainer"],["dc.contributor.author","Pflugmann, Thomas"],["dc.contributor.author","Wullich, Bernd"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Otto, Wolfgang"],["dc.contributor.author","Stoeckle, Michael"],["dc.contributor.author","Jung, Volker"],["dc.date.accessioned","2018-11-07T09:18:33Z"],["dc.date.available","2018-11-07T09:18:33Z"],["dc.date.issued","2013"],["dc.description.abstract","Collecting duct carcinoma (CDC) is a rare renal neoplasm that is associated with poor prognosis due to its highly aggressive course and limited response to immuno-or chemotherapy. Histologically, CDC is defined as a subtype of renal cell carcinomas, but in some cases, it is difficult to differentiate from urothelial carcinomas (UC). Therefore the aim of this study was to determine genetic alterations of CDC in comparison to that of urothelial carcinomas of the upper urinary tract (UUT-UC) to clarify the histological origin of this rare tumor entity. Twenty-nine CDC samples were obtained from seven different German centers and compared with twenty-six urothelial carcinomas of the upper urinary tract. Comparative genomic hybridization (CGH) was used to investigate the genetic composition of patients' tumors and allowed the detection of losses and gains of DNA copy numbers throughout the entire genome. The clinical data were correlated with CGH results. CGH analysis of CDC revealed DNA aberrations in many chromosomes. DNA losses were more frequently observed than gains, while high-level amplifications were not detected. The mean frequency of CDC chromosomal aberrations (4.9/case) was slightly lower than that in UUT-UC (5.4/case). Recurrent CDC DNA losses occurred at 8p (n=9/29), 16p (9/29), 1p (n=7/29) and 9p (n=7/29), and gains occurred in 13q (n= 9/29). In contrast to CDC, the most frequently detected UUT-UC DNA aberration was a loss at 9q (n=13/26). DNA losses at 9q, 13q and 8q as well as gains at 8p showed significant variations in UUT-UC compared to CDC. There was no correlation between the patients' clinical course and the presence or absence of these recurrent genetic alterations. CDCs are characterized by a different genetic pattern compared to UUT-UC. Regarding the published data on renal cell carcinoma, we conclude that CDC appears to be a unique entity among kidney carcinomas."],["dc.identifier.doi","10.1371/journal.pone.0078137"],["dc.identifier.isi","000326034500060"],["dc.identifier.pmid","24167600"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9433"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28430"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","Collecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]